SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

$PHVS
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $PHVS alert in real time by email
SC 13G/A 1 tm245717d1_sc13ga.htm SC 13G/A

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Schedule 13G
(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d)
AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

(Amendment No. 3)*

 

Pharvaris N.V.

(Name of Issuer)

 

Ordinary Shares, par value €0.12

(Title of Class of Securities)

 

N69605108

(CUSIP Number)

 

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)

xRule 13d-1(c)

¨Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

(Continued on following pages)

 

Page 1 of 12

 

Exhibit Index on Page 11

 

 

 

 

 

 

CUSIP # N69605108 Page 2 of 12

 

1 NAME OF REPORTING PERSONS          Foresite Capital Fund IV, L.P. (“FCF IV”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)

¨ 

(b)

x

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH

5 SOLE VOTING POWER
4,038,842 shares, except that Foresite Capital Management IV, LLC (“FCM IV”), the general partner of FCF IV, may be deemed to have sole power to vote these shares, and James Tananbaum (“Tananbaum”), the managing member of FCM IV, may be deemed to have sole power to vote these shares.
6 SHARED VOTING POWER
See response to row 5.
7

SOLE DISPOSITIVE POWER

4,038,842 shares, except that FCM IV, the general partner of FCF IV, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to dispose of these shares.

8 SHARED DISPOSITIVE POWER
See response to row 7.

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,038,842

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

7.8%

12 TYPE OF REPORTING PERSON PN

 

 

 

 

CUSIP # N69605108 Page 3 of 12

 

1 NAME OF REPORTING PERSONS          Foresite Capital Management IV, LLC (“FCM IV”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)

¨ 

(b)

x

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH

5 SOLE VOTING POWER
4,038,842 shares, all of which are directly owned by FCF IV. FCM IV, the general partner of FCF IV, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to vote these shares.
6 SHARED VOTING POWER
See response to row 5.
7

SOLE DISPOSITIVE POWER

4,038,842 shares, all of which are directly owned by FCF IV. FCM IV, the general partner of FCF IV, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to dispose of these shares.
8 SHARED DISPOSITIVE POWER
See response to row 7.

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,038,842

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

7.8%

12 TYPE OF REPORTING PERSON OO

 

 

 

 

CUSIP # N69605108 Page 4 of 12

 

1 NAME OF REPORTING PERSONS          Foresite Capital Fund V, L.P. (“FCF V”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)

¨

(b)

x

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH

5 SOLE VOTING POWER
0 shares
6 SHARED VOTING POWER
See response to row 5.
7

SOLE DISPOSITIVE POWER

0 shares
8 SHARED DISPOSITIVE POWER
See response to row 7.

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

0.0%

12 TYPE OF REPORTING PERSON PN

 

 

 

 

CUSIP # N69605108       Page 5 of 12

 

1 NAME OF REPORTING PERSONS                 Foresite Capital Management V, LLC (“FCM V”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)

¨ 

(b)

x

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH
5

SOLE VOTING POWER
0 shares

6

SHARED VOTING POWER
See response to row 5.

7

SOLE DISPOSITIVE POWER
0 shares

8 SHARED DISPOSITIVE POWER
See response to row 7.

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

0
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

0.0%
12 TYPE OF REPORTING PERSON OO

 

 

 

CUSIP # N69605108       Page 6 of 12

 

1 NAME OF REPORTING PERSONS                   James Tananbaum (“Tananbaum”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)

¨

(b)

x

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH
5 SOLE VOTING POWER
4,038,842 shares, all of which are directly owned by FCF IV. Tananbaum is the managing member of FCM IV, which is the general partner of FCF IV. Tananbaum may be deemed to have sole power to vote these shares.
6 SHARED VOTING POWER
See response to row 5.
7

SOLE DISPOSITIVE POWER

4,038,842 shares, all of which are directly owned by FCF IV. Tananbaum is the managing member of FCM IV, which is the general partner of FCF IV. Tananbaum may be deemed to have sole power to dispose of these shares.
8 SHARED DISPOSITIVE POWER
See response to row 7.

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,038,842

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

7.8%
12 TYPE OF REPORTING PERSON IN

 

 

 

 

CUSIP # N69605108 Page 7 of 12

 

ITEM 1(A).NAME OF ISSUER

 

Pharvaris N.V. (the “Issuer”)

 

ITEM 1(B).ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

 

Emmy Noetherweg 2

2333 BK Leiden, The Netherlands

 

ITEM 2(A).NAME OF PERSONS FILING

 

This Schedule is filed by Foresite Capital Fund IV, L.P., a Delaware limited partnership (“FCF IV”), Foresite Capital Management IV, LLC, a Delaware limited liability company (“FCM IV”), Foresite Capital Fund IV, L.P., a Delaware limited partnership (“FCF V”), Foresite Capital Management V, LLC, a Delaware limited liability company (“FCM V”), and James Tananbaum. The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

 

ITEM 2(B).ADDRESS OF PRINCIPAL OFFICE

 

The address for each of the Reporting Persons is:

 

c/o Foresite Capital Management

900 Larkspur Landing Circle, Suite 150
Larkspur, CA 94939

 

ITEM 2(C).CITIZENSHIP

 

See Row 4 of cover page for each Reporting Person.

 

ITEM 2(D).TITLE OF CLASS OF SECURITIES

 

Ordinary Shares, par value €0.12

 

ITEM 2(E)CUSIP NUMBER

 

N69605108

 

ITEM 3.If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

 

Not applicable.

 

 

 

 

CUSIP # N69605108 Page 8 of 12

 

ITEM 4.OWNERSHIP

 

The following information with respect to the ownership of the Ordinary Shares of the Issuer by the persons filing this Statement is provided as of December 31, 2023:

 

(a)Amount beneficially owned:

 

See Row 9 of cover page for each Reporting Person.

 

(b)Percent of Class:

 

See Row 11 of cover page for each Reporting Person.

 

(c)Number of shares as to which such person has:

 

(i)Sole power to vote or to direct the vote:

 

See Row 5 of cover page for each Reporting Person.

 

(ii)Shared power to vote or to direct the vote:

 

See Row 6 of cover page for each Reporting Person.

 

(iii)Sole power to dispose or to direct the disposition of:

 

See Row 7 of cover page for each Reporting Person.

 

(iv)Shared power to dispose or to direct the disposition of:

 

See Row 8 of cover page for each Reporting Person.

 

ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

 

Not applicable.

 

ITEM 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

 

Under certain circumstances set forth in the limited partnership agreements of FCF IV and FCF V and the limited liability company agreements of FCM IV and FCM V the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member.

 

ITEM 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

 

Not applicable.

 

ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

 

Not applicable

 

ITEM 9.NOTICE OF DISSOLUTION OF GROUP.

 

Not applicable

 

 

 

 

CUSIP # N69605108 Page 9 of 12

 

ITEM 10.CERTIFICATION.

 

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 

 

 

CUSIP # N69605108 Page 10 of 12

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 13, 2024

 

  FORESITE CAPITAL FUND IV, L.P.
     
  By: FORESITE CAPITAL MANAGEMENT IV, LLC
  Its: General Partner
     
  By: /s/ James Tananbaum
  Name: James Tananbaum
  Title: Managing Member
     
  FORESITE CAPITAL MANAGEMENT IV, LLC
     
  By: /s/ James Tananbaum
  Name: James Tananbaum
  Title: Managing Member
     
  FORESITE CAPITAL FUND V, L.P.
     
  By: FORESITE CAPITAL MANAGEMENT V, LLC
  Its: General Partner
     
  By: /s/ James Tananbaum
  Name: James Tananbaum
  Title: Managing Member
     
  FORESITE CAPITAL MANAGEMENT V, LLC
     
  By: /s/ James Tananbaum
  Name: James Tananbaum
  Title: Managing Member
     
  JAMES TANANBAUM
     
  By: /s/ James Tananbaum
  Name: James Tananbaum

 

 

 

 

CUSIP # N69605108 Page 11 of 12

 

EXHIBIT INDEX

 

  Found on
Sequentially
Exhibit Numbered Page
   
Exhibit A:  Agreement of Joint Filing 12
   

 

 

 

 

CUSIP # N69605108 Page 12 of 12

 

exhibit A

 

Agreement of Joint Filing

 

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Ordinary Shares of the Issuer shall be filed on behalf of each of the undersigned. Note that a copy of the applicable Agreement of Joint Filing is already on file with the appropriate agencies.

 

 

 

Get the next $PHVS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PHVS

DatePrice TargetRatingAnalyst
9/25/2023$27.00Outperform
Wedbush
8/15/2023$10.00 → $34.00Equal-Weight → Overweight
Morgan Stanley
10/5/2022$16.00Buy
Bryan Garnier
9/13/2022$34.00 → $18.00Mkt Outperform
JMP Securities
8/23/2022$40.00 → $10.00Overweight → Equal-Weight
Morgan Stanley
8/22/2022$26.00 → $13.00Neutral → Underperform
BofA Securities
5/25/2022$34.00Mkt Outperform
JMP Securities
More analyst ratings

$PHVS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

    Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero daysAll participants in CHAPTER-1 OLE who had reached week 62 reported improved health-related quality of lifeOngoing RAPIDe-2 extension study includes efficacy data from seven upper airway, including laryngeal, attacks; median time to onset of symptom relief was 0.9 hours (N=7)In both extension studies, deucrictibant was generally well tolerated with no safety signals observed ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradyki

    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

    ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place from March 10-12, 2025, at the W South Beach Hotel in Miami, FL. Details are as follows: Format:Fireside ChatRepresentative: Berndt Modig, CEO of PharvarisDate & Time: Monday, March 10, 9:20 a.m. ET   A live audi

    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Pharvaris Outlines 2025 Strategic Priorities

    Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H2026Enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026Study initiation of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH) anticipated in 2025Operating from a strong financial position with estimated cash runway into 3Q2026Company presentation at the J.P. Morgan Healthcare Conference ZUG, Switzerland, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-st

    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PHVS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PHVS
SEC Filings

See more

$PHVS
Leadership Updates

Live Leadership Updates

See more
  • Vicore Expands and Strengthens its Board of Directors

    STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

    $KRON
    $MACK
    $MXCT
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Biotechnology: Laboratory Analytical Instruments
  • Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

    ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer. In this role, he will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development. Dr. Abele joins Pharvaris with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities

    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update

    Formal letters received from FDA relating to the previously announced hold on clinical studies of PHA121 in the U.S.Top-line data anticipated in 4Q22 for RAPIDe-1, a global Phase 2 study of PHVS416 for the acute treatment of HAE attacks ongoing outside the U.S.Executing from a strong financial position with cash and cash equivalents of €201 million as of June 30, 2022 ZUG, Switzerland, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the second quarter ended June 30, 2022, and provided a business update

    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PHVS
Financials

Live finance-specific insights

See more
  • Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

    CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rece

    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

    Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo92.3% reduction in occurrence of moderate and severe attacks92.6% fewer attacks treated with on-demand medication by participantsDeucrictibant well-toleratedPharvaris to host a conference call today at 8:00 a.m. EST ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoi

    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

    Primary endpoint met, substantially reducing HAE attack symptomsAll secondary endpoints metPHVS416 was well tolerated at all dose levelsPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks. Pharvaris plans to present data from the study at future medical meetings. RAPIDe-1 Clinical Stu

    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PHVS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more